Highest-materiality recent filing
Incyte Q2 revenue $1.67B (+38% YoY); raises FY2026 guidance; acquires Vega Therapeutics for $1.25B
Total net sales $1.49B (+40% YoY); GAAP diluted EPS $2.81, Non-GAAP diluted EPS $3.09.
Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039
Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
Incyte settles CMS dispute over Opzelura Medicaid rebates; records $246M benefit
CMS will not apply line extension regulation to Opzelura as if it were a line extension of Jakafi; Incyte withdraws lawsuit.
Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B
Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.
Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands
Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings
FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.
Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance
Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B
GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.
Incyte CFO Christiana Stamoulis to step down effective September 16, 2025
CFO Christiana Stamoulis notified Incyte of her resignation to pursue another opportunity.
Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance
Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
Incyte appoints William J. Meury as President and CEO; Hervé Hoppenot retires
Hervé Hoppenot retired as President & CEO effective June 26, 2025; will serve as special advisor for up to one year.
Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued
Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.
Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised
Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.
Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M
Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised
Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed
Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).
Incyte commences $1.672B Dutch auction tender offer, agrees to buy $328M from Baker Entities
Incyte commences modified Dutch auction tender offer to repurchase up to $1.672 billion of common stock at $52-$60 per share.
Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M
Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.
Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024
Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.
Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B
Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).
Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs
Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).
Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B
Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).
Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance
FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.
Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M
Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).
Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end
Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).
Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong
Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).
Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B
Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).
Incyte reports 3 product complaints for Opzelura cream; suspends affected batches
Three product complaints received for Opzelura (ruxolitinib) cream related to texture.
Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals
Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).
Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year
Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).
On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.
On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023.
Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.
On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders.
Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer).
On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022.
Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.
Max materiality 0.90 · Median 0.75 · Most common event earnings